First quarter 2018, compared to 2017, Group
- Group net sales increased by 135% to SEK 1.1m (0.5)
- Gross order intake amounted to SEK 0.9m (0.7) an increase of 10.1%
- Order backlog amounted to SEK 0.5m (0.5)
- 34% growth in orders for Episealer® knee implants during the quarter with 39 (29) approved orders
- Loss before tax amounted to SEK –13.3m (–19.0)
- Earnings per share (weighted average) amounted to SEK –0.44 (–0.94)
Significant events during the first quarter
- Episurf Medical continued regulatory preparations and industrial partnership discussions in the US
- Episurf Medical received market approval in Israel and signed distribution agreement for the Israeli market
- Episurf Medical announced that the company is in the final stages of the development of an ankle implant
- Episurf Medical signed financing agreement of up to SEK 70m which was approved at the AGM April 9th, 2018
- Episurf Medical received another patent approval in the US related to Episurf Medical’s 3D-based damage assessment tool
- Episurf Medical presented long-term financial and operating targets
Significant events after the first quarter
- Episealer® clinical outcome was presented at the 2018 world congress of International Cartilage Repair Society (ICRS) In Macau
- Promising clinical results from use of Episealer® were presented at the annual meeting of British Association for Surgery of the Knee
- Episurf Medical’s knee products approved for marketing and sale in Spain
- Episurf Medical entered into a distribution agreement in Hong Kong and established subsidiary In the US
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
